skip to main content

CCB-induced Peripheral Oedema — EECC MCQ

Instant feedback + full explanation. One question, done properly.

EasyHypertension & Preventive CardiologyCCB-induced Peripheral OedemaEECC

A 75-year-old woman with hypertension on amlodipine develops bilateral ankle oedema. Her JVP is normal, lungs are clear, and there is no evidence of heart failure. What is the cause and management?

Educational content. Not a substitute for clinical judgement or local policy.

Reveal the answer and explanation

Correct answer: A — Dihydropyridine CCB-induced peripheral oedema — caused by precapillary arteriolar vasodilation with postcapillary venous pressure gradient, leading to fluid transudation; reducing dose, adding an ACEi/ARB (which dilates postcapillary venules), or switching drug class is recommended

Peripheral oedema is the most common adverse effect of dihydropyridine CCBs (amlodipine, nifedipine, felodipine), occurring in 10-30% of patients (dose-dependent). The mechanism is NOT fluid retention — it results from preferential precapillary arteriolar vasodilation (without matched postcapillary venular dilation), creating a pressure gradient that forces fluid into the interstitium. Diuretics are ineffective (as the oedema is redistributive, not volume-related). Management options: (1) Add an ACEi/ARB — these dilate postcapillary venules, reducing the pressure gradient and oedema (the ACCOMPLISH trial combination of amlodipine + benazepril had less oedema than amlodipine alone); (2) Dose reduction; (3) Switch to a different antihypertensive class. The 2024 ESC Hypertension Guidelines recommend SPC of CCB + ACEi/ARB as first-line partly for this reason.

Reference: ESC (2024): Hypertension Guidelines